These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 9740703)

  • 1. Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study.
    Rose PG; Blessing JA; Soper JT; Barter JF
    Gynecol Oncol; 1998 Aug; 70(2):267-71. PubMed ID: 9740703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
    Rose PG; Blessing JA; Van Le L; Waggoner S
    Gynecol Oncol; 1998 Aug; 70(2):263-6. PubMed ID: 9740702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group.
    Smith HO; Blessing JA; Vaccarello L
    Gynecol Oncol; 2002 Jan; 84(1):140-4. PubMed ID: 11748990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
    Sutton G; Blessing J; Hanjani P; Kramer P;
    Gynecol Oncol; 2005 Mar; 96(3):749-52. PubMed ID: 15721421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study.
    Rose PG; Blessing JA; Lewandowski GS; Creasman WT; Webster KD
    Gynecol Oncol; 1996 Oct; 63(1):101-4. PubMed ID: 8898177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of prolonged oral etoposide in advanced or recurrent carcinoma of the cervix.
    Morris M; Brader KR; Burke TW; Levenback CF; Gershenson DM
    Gynecol Oncol; 1998 Aug; 70(2):215-8. PubMed ID: 9740693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of etoposide in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
    Thigpen T; Blessing JA; Yordan E; Valea F; Vaccarello L
    Gynecol Oncol; 1996 Oct; 63(1):120-2. PubMed ID: 8898180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a gynecologic oncology group study.
    Sutton G; Blessing JA; Ball H
    Gynecol Oncol; 1999 Sep; 74(3):346-9. PubMed ID: 10479491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of oral etoposide in recurrent or refractory endometrial adenocarcinoma: a southwest oncology group study.
    Poplin EA; Liu PY; Delmore JE; Wilczynski S; Moore DF; Potkul RK; Fine BA; Hannigan EV; Alberts DS
    Gynecol Oncol; 1999 Sep; 74(3):432-5. PubMed ID: 10479505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
    Rose PG; Blessing JA; Buller RE; Mannel RS; Webster KD
    Gynecol Oncol; 2003 May; 89(2):267-70. PubMed ID: 12713990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage chemotherapy for recurrent spinal cord ependymona.
    Chamberlain MC
    Cancer; 2002 Sep; 95(5):997-1002. PubMed ID: 12209682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II evaluation of oral trimetrexate in mixed mesodermal tumors of the uterus: a gynecologic oncology group study.
    Fowler JM; Blessing JA; Burger RA; Malfetano JH
    Gynecol Oncol; 2002 May; 85(2):311-4. PubMed ID: 11972393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of hydroxyurea, dacarbazine (DTIC), and etoposide (VP-16) in mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study.
    Currie JL; Blessing JA; McGehee R; Soper JT; Berman M
    Gynecol Oncol; 1996 Apr; 61(1):94-6. PubMed ID: 8626125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of prolonged oral etoposide and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.
    Rose PG; Rodriguez M; Walker J; Greer B; Fusco N; McGuire W
    Gynecol Oncol; 2002 Apr; 85(1):136-9. PubMed ID: 11925133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of dacarbazine, mitomycin, doxorubicin, and cisplatin with sargramostim in uterine leiomyosarcoma: a Gynecologic Oncology Group study.
    Long HJ; Blessing JA; Sorosky J
    Gynecol Oncol; 2005 Nov; 99(2):339-42. PubMed ID: 16051328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
    Miller AA; Al Omari A; Murry DJ; Case D
    Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
    Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study.
    Rose PG; Markman M; Bell JG; Fusco NL
    Gynecol Oncol; 2006 Aug; 102(2):236-9. PubMed ID: 16412499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
    McMeekin DS; Sill MW; Darcy KM; Stearns-Kurosawa DJ; Webster K; Waggoner S; Benbrook D
    Gynecol Oncol; 2007 Sep; 106(3):596-603. PubMed ID: 17597196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC).
    Alici S; Saip P; Eralp Y; Aydiner A; Topuz E
    Am J Clin Oncol; 2003 Aug; 26(4):358-62. PubMed ID: 12902885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.